Loading...
Market
What will be the outcome of the Senate Health Committee's actions on drug pricing by the end of 2024?
2
Bernie Sanders•Novo Nordisk•Ozempic•Wegovy•Senate Health Committee•Sanders•Senate Health Cmte•Cigna•CVSHealth•UHC•Jorgenson•Bill Cassidy
Resolution / Starting Odds
Legislation passed • 25%
Non-binding resolution • 25%
No action taken • 25%
Other • 25%
Official announcements from the Senate Health Committee or verified news reports
Story
Sanders Urges Novo Nordisk to Cut Ozempic, Wegovy Prices at Tuesday's Hearing
Sep 24, 2024, 03:30 PM
Senator Bernie Sanders has called for a reduction in the list prices of Novo Nordisk's weight-loss drugs, Ozempic and Wegovy, during Tuesday's Senate Health Committee hearing. Sanders, the Senate Health Cmte Chair, emphasized that the high costs of these medications are a result of a dysfunctional healthcare system. Pharmacy Benefit Managers (PBMs), including Cigna, CVSHealth, and UHC, have committed to expanding coverage for these drugs if Novo Nordisk lowers their prices. Novo Nordisk CEO Jorgenson stated that the list price is merely a starting point for negotiations with PBMs and insurance companies. Despite Sanders' pressure, Jorgenson did not explicitly commit to significantly lowering the prices. GOP Senator Bill Cassidy argued that the issue of high drug prices is complex and cannot be solely blamed on big pharmaceutical companies.
View original story
Similar markets
No action taken • 25%
Recommendations for price reductions • 25%
Legislation introduced • 25%
Other • 25%
Fines imposed • 25%
Regulations introduced • 25%
No action taken • 25%
Other • 25%
Significantly lower • 25%
Moderately lower • 25%
No change • 25%
Higher • 25%
Democratic Party • 25%
Republican Party • 25%
Bipartisan Support • 25%
Other • 25%
New federal regulation • 25%
New state-level regulations • 25%
No regulatory change • 25%
Other changes • 25%
